COURAGE
2007
Clinical Outcomes Utilising Revascularisation and Aggressive Drug Evaluation
In 2,287 patients with stable coronary artery disease, PCI added to optimal medical therapy did not reduce death or non-fatal MI compared with optimal medical therapy alone.
Result
Efficacy: Death or non-fatal MIHR 1.05
Below 1 favours PCI added to optimal medical therapy, above 1 favours optimal medical therapy alone.
- Absolute difference
- 0.5 points
The absolute difference is derived from the event rates.
Also reported: Angina relief favoured PCI early but converged by 5 yr.
- Subtopic
- Revascularisation
- Design
- RCT, median 4.6 yr
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2024 CCSESC/EACTS 2018 RevascularisationACC/AHA 2023 CCDACC/AHA 2021 RevascularisationAHA/ACC 2021 Chest Pain
- Source
- Boden WE, et al. N Engl J Med. 2007;356(15):1503-1516.doi 10.1056/NEJMoa070829
Discussion & critique
Bare-metal stent era, ~ 30 % crossover from medical arm to PCI. Did not include FFR guidance. Still the conceptual anchor for medical-therapy-first.